Research

Clinical Trials

About this page

This section of the website is used to post information about relevant clinical trials in Canada as we are made aware of them. At the Foundation, we recommend you ask your doctor whether there are any clinical trials going on that you may be able to join. This has two benefits: firstly, you will have the opportunity to try new drugs that, hopefully, will come on the market and which may help you; and secondly, you are contributing to important research and that will make you feel good.

Clinical Trials and Drug Safety in Canada

Why Participate in a Clinical Trial

Dr. Gerard (Gerry) Cox talks briefly about what a clinical trial is, how a clinical trial is run, generally what drugs are being tested for IPF, and why you should participate in a clinical trial. The video is a recording of an interview with Dr. Cox shown to high school students from Hamilton, Ontario on December 2nd, 2013.

Clinical Trials in Canada

If you become aware of a relevant clinical trial for pulmonary fibrosis patients, please contact us at news.cpff@gmail.com and we will add it here.

Nebulized Fentanyl in Patients With Mild to Moderate IPF and Chronic Dyspnea
Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea – Phase 3

https://clinicaltrials.gov/ct2/show/study/NCT03018756

Sponsored by Queen’s University

Study Locations as of Jan. 12, 2017:  (Recruiting) Kingston, ON.

Evaluate the Efficacy and Safety of CC-90001 in Subjects With IPF
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis – Phase 2

https://clinicaltrials.gov/ct2/show/study/NCT03142191

Sponsored by Celgene

Study Locations (as of Oct. 13, 2017):  (Recruiting) Kelowna, BC; Vancouver, BC.  (Not yet recruiting)  London, ON.

Efficacy and Safety of Nintedanib When Co-administered With Sildenafil
Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment – Phase 3

https://clinicaltrials.gov/ct2/show/study/NCT02802345

Sponsored by Boehringer Ingelheim

Study Locations (as of Oct. 4, 2017):  (Recruiting) Vancouver, BC. (Active, not recruiting)  Edmonton, AB; Hamilton, ON; Toronto, ON.

High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib (HOPE-IPF)
High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib (HOPE-IPF)

https://clinicaltrials.gov/ct2/show/study/NCT02551068

Sponsored by University of British Columbia
Collaborator Boehringer Ingelheim

Study Locations as of May 16, 2017:  (Recruiting) Kelowna, BC; Vancouver, BC; Edmonton, AB; Kingston, ON; Montreal, QC; Quebec City, QC   (Not yet recruiting) Calgary, AB; Hamilton, ON

The following studies are ongoing, but not recruiting participants.

FG-3019 for Patients with IPF
Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis – Phase 2

https://clinicaltrials.gov/ct2/show/study/NCT01890265

Sponsored by FibroGen — intravenous infusion every 3 weeks.

Study Locations as of Aug. 22, 2017:  This study is ongoing, but not recruiting participants.

Observational Study Esbriet {Pirfenidone)
Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada – Phase 4

https://clinicaltrials.gov/ct2/show/study/NCT02552849

Study Locations as of Oct. 3, 2017:  Study is ongoing but not recruiting participants.

Lebrikizumab for Patients with IPF
A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis – Phase 2

http://clinicaltrials.gov/ct2/show/NCT01872689

Study Locations as of Jul. 21, 2017:  This study is ongoing, but not recruiting participants.

Efficacy and Safety of Nintedanib
Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) – Phase 3

https://clinicaltrials.gov/ct2/show/study/NCT02999178

Sponsored by Boehringer Ingelheim

Study Locations as of Oct. 4, 2017:  (Recruiting) Winnipeg, MB; Hamilton, ON;  Toronto, ON; Sherbrooke, QC.

Nintedanib for Patients with (SSc-ILD)
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis (SSc-ILD or Systemic Sclerosis related ILD) – Phase 3

https://clinicaltrials.gov/ct2/show/study/NCT02597933

Sponsored by Boehringer Ingelheim — 150 mg capsule twice a day.

Study Locations as of Oct. 4, 2017:  (Recruiting) Hamilton, ON; Windsor, ON; London, ON; Toronto; ON; Montreal, QC

Abituzumab in SSc-ILD)
Abituzumab in Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) – Phase 2

https://clinicaltrials.gov/ct2/show/study/NCT02745145

Sponsored by EMD Serono Research & Development Institute, Inc.
Collaborator Merck KGaA

The purpose of this trial is to compare two doses of abituzumab with placebo and determine whether abituzumab is more effective, safer, will be better tolerated and can provoke better immune response than placebo in the treatment of patients with SSc-ILD who already receive constant doses of mycophenolate.

Intravenous infusion over approximately 1 hour every 4 weeks for 104 weeks with either 1500 mg Abituzumab or 500 mg Abituzumab or placebo

Study Locations as of Jul. 28, 2017:  (Recruiting) Vancouver, BC; Toronto, ON